Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Nanomedicine ; 17: 266-275, 2019 04.
Article in English | MEDLINE | ID: mdl-30794962

ABSTRACT

The complement system plays an essential role in both innate and adaptive immunity. The traditional understanding of this system comes from studies investigating complement proteins produced by the liver and present in plasma to "complement" the immune cell-mediated response to invading pathogens. Recently, it has been reported that immune cells including, but not limited to, T-cells and monocytes, express complement proteins. This complement is referred to as intracellular (IC) and implicated in the regulation of T-cell activation. The mechanisms and the structure-activity relationship between nanomaterials and IC, however, are currently unknown. Herein, we describe a structure-activity relationship study demonstrating that under in vitro conditions, only polymeric materials with cationic surfaces activate IC in T-cells. The effect also depends on particle size and occurs through a mechanism involving membrane damage, thereby IC on the cell surface serves as a self-opsonization marker in response to the nanoparticle-triggered danger affecting the cell integrity.


Subject(s)
Complement Activation , Lymphocyte Activation , Nanoparticles/adverse effects , Polymers/adverse effects , T-Lymphocytes/immunology , Cations/adverse effects , Cations/chemistry , Cells, Cultured , Complement Activation/drug effects , Humans , Jurkat Cells , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Nanoparticles/chemistry , Polymers/chemistry , T-Lymphocytes/drug effects
2.
Toxicol Appl Pharmacol ; 299: 70-7, 2016 May 15.
Article in English | MEDLINE | ID: mdl-26773813

ABSTRACT

Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody formation exist and how they challenge the application of nanoparticles for drug delivery. Moreover, it has been recognized that accidental contamination of therapeutic protein formulations with nanosized particulate materials may contribute to the immunogenicity of this type of biotechnology products. While the immunological properties of engineered nanomaterials and their application as vaccine carriers and adjuvants have been given substantial consideration in the current literature, little attention has been paid to nanoparticle immuno- and antigenicity. To fill in this gap, we herein provide an overview of this subject to highlight the current state of the field, review past and present research, and discuss future research directions.


Subject(s)
Antigenic Modulation/immunology , Comprehension , Immunity, Cellular/immunology , Immunogenetic Phenomena/immunology , Nanostructures/toxicity , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/toxicity , Animals , Antigenic Modulation/drug effects , Drug Carriers/administration & dosage , Drug Carriers/toxicity , Drug Delivery Systems/adverse effects , Drug Delivery Systems/methods , Forecasting , Humans , Immunity, Cellular/drug effects , Immunogenetic Phenomena/drug effects , Nanostructures/administration & dosage
3.
Nanomedicine ; 11(8): 1925-38, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26282378

ABSTRACT

Understanding the ability of cytotoxic oncology drugs, and their carriers and formulation excipients, to induce pro-inflammatory responses is important for establishing safe and efficacious formulations. Literature data about cytokine response induction by the traditional formulation of paclitaxel, Taxol®, are controversial, and no data are available about the pro-inflammatory profile of the nano-albumin formulation of this drug, Abraxane®. Herein, we demonstrate and explain the difference in the cytokine induction profile between Taxol® and Abraxane®, and describe a novel mechanism of cytokine induction by a nanosized excipient, Cremophor EL, which is not unique to Taxol® and is commonly used in the pharmaceutical industry for delivery of a wide variety of small molecular drugs. FROM THE CLINICAL EDITOR: Advances in nanotechnology have enabled the production of many nano-formulation drugs. The cellular response to drugs has been reported to be different between traditional and nano-formulations. In this article, the authors investigated and compared cytokine response induction profiles between Taxol® and Abraxane®. The findings here provided further understanding to create drugs with better safety profiles.


Subject(s)
Albumin-Bound Paclitaxel/adverse effects , Antineoplastic Agents/adverse effects , Glycerol/analogs & derivatives , Oxidative Stress/drug effects , Paclitaxel/adverse effects , Pharmaceutical Vehicles/adverse effects , Polyethylene Glycols/adverse effects , Animals , Cell Line , Glycerol/adverse effects , Humans , Interleukin-8/blood , Interleukin-8/metabolism , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Mice
4.
Methods Mol Biol ; 2789: 109-120, 2024.
Article in English | MEDLINE | ID: mdl-38506996

ABSTRACT

The complement system is complex and includes two main components: the systemic or plasma complement and the so-called intracellular complement or complosome. The complement proteins expressed by the liver and secreted into blood plasma compose the plasma complement system, whereas complement proteins expressed by and functioning inside the cell represent the intracellular complement. The complement system plays an essential role in host defense; however, complement activation may lead to pathologies when uncontrolled. When such undesirable activation of the plasma complement occurs in response to a drug product, it leads to immediate-type hypersensitivity reactions independent of immunoglobulin E. These reactions are often called complement activation-related pseudoallergy (CARPA). In addition to the blood plasma, the complement protein C3 is found in many cells, including lymphocytes, monocytes, endothelial, and even cancer cells. The activation of the intracellular complement generates split products, which are exported from the cell onto the membrane. Since the activation of the intracellular complement in T lymphocytes was found to correlate with autoimmune disorders, and growing evidence is available for the involvement of T lymphocytes in the development of drug-induced hypersensitivity reactions, understanding the ability of nanomaterials to activate intracellular complement may aid in establishing a long-term safety profile for these materials. This chapter describes a flow cytometry-based protocol for detecting intracellular complement activation by engineered nanomaterials.


Subject(s)
Drug Hypersensitivity , Nanoparticles , Humans , T-Lymphocytes , Complement Activation , Complement System Proteins , Complement C3 , Nanoparticles/adverse effects
5.
J Virol ; 86(5): 2447-58, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22171268

ABSTRACT

We used replication-dependent retroviral vectors to identify cell surface antigens involved in the cell-to-cell transmission of human T cell leukemia virus type 1 (HTLV-1). We generated monoclonal antibodies (MAbs) against Jurkat T cells and selected several IgM MAbs that strongly inhibited HTLV-1 but not human immune deficiency virus type 1 (HIV-1) cell-to-cell infection. These MAbs recognized the so-called Tn antigen (GalNAcα1-O-Ser/Thr) that arises on Jurkat cells from a mutation in the T-synthase-specific chaperone Cosmc and the consequent loss of O-glycan elongation. Anti-Tn MAbs precipitated two major O-glycan carrier proteins, CD43 and CD45, and caused a strong aggregation of Jurkat cells. The restoration of O-glycosylation in Jurkat cells by stably transducing the wild-type Cosmc gene resulted in a 3- to 4-fold increase in the level of surface expression of CD43 and enhanced HTLV-1 transmission 10-fold in comparison to that of parental cells. The short hairpin RNA (shRNA) knockdown of CD43 or CD45 expression in Jurkat-Cosmc, HBP-ALL, and CEM T cells decreased HTLV-1 infection severalfold. The knockdown of CD45 in Jurkat cells severely reduced both HTLV-1 and HIV-1 infections, but Cosmc coexpression partially rescued infection. HTLV-1 proteins, which assembled in small patches on Jurkat cells, formed large clusters on the surface of Jurkat-Cosmc cells. These data indicate that large aggregates of HTLV-1 assemblies are more infectious than multiple clustered virions. We suggest that heavily O-glycosylated CD43 and CD45 molecules render cells less adhesive, prevent inappropriate cell-cell contacts, and favor the assembly of HTLV-1 particles into large, highly infectious structures on the surface of T cells.


Subject(s)
Gene Expression , HTLV-I Infections/genetics , HTLV-I Infections/metabolism , Human T-lymphotropic virus 1/physiology , Leukocyte Common Antigens/metabolism , Leukosialin/metabolism , T-Lymphocytes/metabolism , Glycosylation , HTLV-I Infections/virology , Humans , Jurkat Cells , Leukocyte Common Antigens/genetics , Leukosialin/genetics , T-Lymphocytes/virology
6.
AAPS J ; 25(4): 61, 2023 06 20.
Article in English | MEDLINE | ID: mdl-37340133

ABSTRACT

Mucopolysaccharidosis type II, commonly called Hunter syndrome, is a rare X-linked recessive disease caused by the deficiency of the lysosomal enzyme iduronate-2-sulphatase (I2S). A deficiency of I2S causes an abnormal glycosaminoglycans accumulation in the body's cells. Although enzyme replacement therapy is the standard therapy, adeno-associated viruses (AAV)-based gene therapy could provide a single-dose solution to achieve a prolonged and constant enzyme level to improve patient's quality of life. Currently, there is no integrated regulatory guidance to describe the bioanalytical assay strategy to support gene therapy products. Herein, we describe the streamlined strategy to validate/qualify the transgene protein and its enzymatic activity assays. The method validation for the I2S quantification in serum and method qualification in tissues was performed to support the mouse GLP toxicological study. Standard curves for I2S quantification ranged from 2.00 to 50.0 µg/mL in serum and 6.25 to 400 ng/mL in the surrogate matrix. Acceptable precision, accuracy, and parallelism in the tissues were demonstrated. To assess the function of the transgene protein, fit-for-purpose method qualification for the I2S enzyme activity in serum was performed. The observed data indicated that the enzymatic activity in serum increased dose-dependently in the lower I2S concentration range. The highest I2S transgene protein was observed in the liver among tissue measured, and its expression level was maintained up to 91 days after the administration of rAAV8 with a codon-optimized human I2S. In conclusion, the multifaceted bioanalytical method for I2S and its enzymatic activity were established to assess gene therapy products in Hunter syndrome.


Subject(s)
Iduronate Sulfatase , Mucopolysaccharidosis II , Humans , Animals , Mice , Mucopolysaccharidosis II/therapy , Mucopolysaccharidosis II/drug therapy , Iduronic Acid , Quality of Life , Iduronate Sulfatase/genetics , Iduronate Sulfatase/therapeutic use , Genetic Therapy , Enzyme Replacement Therapy/methods
7.
Eur J Clin Nutr ; 77(8): 803-810, 2023 08.
Article in English | MEDLINE | ID: mdl-37311868

ABSTRACT

BACKGROUND: Lactase persistence-the ability to digest lactose through adulthood-is closely related to evolutionary adaptations and has affected many populations since the beginning of cattle breeding. Nevertheless, the contrast initial phenotype, lactase non-persistence or adult lactase deficiency, is still observed in large numbers of people worldwide. METHODS: We performed a multiethnic genetic study of lactase deficiency on 24,439 people, the largest in Russia to date. The percent of each population group was estimated according to the local ancestry inference results. Additionally, we calculated frequencies of rs4988235 GG genotype in Russian regions using the information of current location and birthplace data from the client's questionnaire. RESULTS: The attained results show that among all studied population groups, the frequency of GG genotype in rs4988235 is higher than the average in the European populations. In particular, the prevalence of lactase deficiency genotype in the East Slavs group was 42.8% (95% CI: 42.1-43.4%). We also investigated the regional prevalence of lactase deficiency based on the current place of residence. CONCLUSIONS: Our study emphasizes the significance of genetic testing for diagnostics, i.e., specifically for lactose intolerance parameter, as well as the scale of the problem of lactase deficiency in Russia which needs to be addressed by the healthcare and food sectors.


Subject(s)
Lactose Intolerance , Humans , Animals , Cattle , Lactose Intolerance/epidemiology , Lactose Intolerance/genetics , Lactase/genetics , Lactose , Genotype , Phenotype , Polymorphism, Single Nucleotide
8.
Eur J Clin Nutr ; 77(5): 574-578, 2023 05.
Article in English | MEDLINE | ID: mdl-36690773

ABSTRACT

BACKGROUND: Overweight is the scourge of modern society and a major risk factor for many diseases. For this reason, understanding the genetic component predisposing to high body mass index (BMI) seems to be an important task along with preventive measures aimed at improving eating behavior and increasing physical activity. METHODS: We analyzed genetic data of a European cohort (n = 21,080, 47.25% women, East Slavs ancestry >80%) for 5 frequently found genes in the context of association with obesity: IPX3 (rs3751723), MC4R (rs17782313), TMEM18 (rs6548238), PPARG (rs1801282) and FTO (rs9939609). RESULTS: Our study revealed significant associations of FTO (rs9939609) (ß = 0.37 (kg/m2)/allele, p = <2 × 10-16), MC4R (rs17782313) (ß = 0.28 (kg/m2)/allele, p = 5.79 × 10-9), TMEM18 (rs6548238) (ß = 0.29 (kg/m2)/allele, p = 2.43 × 10-8) with BMI and risk of obesity. CONCLUSIONS: The results confirm the contribution of FTO, M4CR, and TMEM18 genes to the mechanism of body weight regulation and control.


Subject(s)
Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Humans , Female , Male , Body Mass Index , Obesity/genetics , Obesity/epidemiology , Body Weight , Genotype , Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics
9.
J Int Med Res ; 51(10): 3000605231206294, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37910852

ABSTRACT

Joubert syndrome (JS) is a recessive disorder that is characterized by midbrain-hindbrain malformation and shows the "molar tooth sign" on magnetic resonance imaging. Mutations in 40 genes, including Abelson helper integration site 1 (AHI1), inositol polyphosphate-5-phosphatase (INPP5E), coiled-coil and c2 domain-containing protein 2A (CC2D2A), and ARL2-like protein 1 (ARL13B), can cause JS. Classic JS is a part of a group of diseases associated with JS, and its manifestations include various neurological signs such as skeletal abnormalities, ocular coloboma, renal disease, and hepatic fibrosis. Here, we present a proband with the molar tooth sign, ataxia, and developmental and psychomotor delays in a Dagestan family from Russia. Molecular genetic testing revealed two novel heterozygous variants, c.2924G>A (p.Arg975His) in exon 28 and c.1241C>G (p.Pro414Arg) in exon 12 of the transmembrane protein 67 (TMEM67) gene. These TMEM67 gene variants significantly affected the development of JS type 6. This case highlights the importance of whole exome sequencing for a proper clinical diagnosis of children with complex motor and psycho-language delays. This case also expands the clinical phenotype and genotype of TMEM67-associated diseases.


Subject(s)
Abnormalities, Multiple , Eye Abnormalities , Kidney Diseases, Cystic , Child , Humans , Abnormalities, Multiple/diagnosis , Abnormalities, Multiple/genetics , Eye Abnormalities/diagnosis , Eye Abnormalities/genetics , Eye Abnormalities/pathology , Cerebellum/diagnostic imaging , Kidney Diseases, Cystic/diagnosis , Kidney Diseases, Cystic/genetics , Kidney Diseases, Cystic/pathology , Retina/diagnostic imaging , Retina/pathology , Phosphoric Monoester Hydrolases/genetics , Mutation/genetics , Membrane Proteins/genetics , GTP-Binding Proteins/genetics
10.
PLoS Pathog ; 6(2): e1000788, 2010 Feb 26.
Article in English | MEDLINE | ID: mdl-20195464

ABSTRACT

We have developed an efficient method to quantify cell-to-cell infection with single-cycle, replication dependent reporter vectors. This system was used to examine the mechanisms of infection with HTLV-1 and HIV-1 vectors in lymphocyte cell lines. Effector cells transfected with reporter vector, packaging vector, and Env expression plasmid produced virus-like particles that transduced reporter gene activity into cocultured target cells with zero background. Reporter gene expression was detected exclusively in target cells and required an Env-expression plasmid and a viral packaging vector, which provided essential structural and enzymatic proteins for virus replication. Cell-cell fusion did not contribute to infection, as reporter protein was rarely detected in syncytia. Coculture of transfected Jurkat T cells and target Raji/CD4 B cells enhanced HIV-1 infection two fold and HTLV-1 infection ten thousand fold in comparison with cell-free infection of Raji/CD4 cells. Agents that interfere with actin and tubulin polymerization strongly inhibited HTLV-1 and modestly decreased HIV-1 cell-to-cell infection, an indication that cytoskeletal remodeling was more important for HTLV-1 transmission. Time course studies showed that HTLV-1 transmission occurred very rapidly after cell mixing, whereas slower kinetics of HIV-1 coculture infection implies a different mechanism of infectious transmission. HTLV-1 Tax was demonstrated to play an important role in altering cell-cell interactions that enhance virus infection and replication. Interestingly, superantigen-induced synapses between Jurkat cells and Raji/CD4 cells did not enhance infection for either HTLV-1 or HIV-1. In general, the dependence on cell-to-cell infection was determined by the virus, the effector and target cell types, and by the nature of the cell-cell interaction.


Subject(s)
Cell Communication/physiology , Deltaretrovirus Infections/transmission , Genetic Vectors , HIV Infections/transmission , Lymphocytes/virology , Virion/physiology , Cell Separation , Coculture Techniques , Flow Cytometry , Genes, Reporter , HIV-1/physiology , Human T-lymphotropic virus 1/physiology , Humans , Jurkat Cells , Transfection , Virus Replication
11.
J Int Med Res ; 50(12): 3000605221139718, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36567457

ABSTRACT

Charcot-Marie-Tooth disease (CMT) is a genetically heterogeneous group of peripheral neuropathies most of which are associated with mutations in four genes including peripheral myelin protein-22 (PMP22), myelin protein zero (MPZ), gap junction protein beta1 (GJB1) and mitofusin2 (MFN2). This current case report describes the clinical and genetic characteristics of a 6-year-old male proband. A physical examination revealed muscular hypotonia. He started walking on his own at 18 months. A nerve conduction study with needle electromyography revealed conduction block. A novel MPZ mutation (c.398C > T, p.Pro133Leu) was revealed in the proband. This mutation was also found in the 32-year-old father of the proband. The father had had deformity of the feet and distal muscle weakness since childhood. The novel p.Pro133Leu pathogenic mutation was responsible for early onset but slowly progressive CMT1B. We assume that this site is an intolerant to change region in the MPZ gene. This variant in the MPZ gene is an important contributor to hereditary neuropathy with reduced nerve conduction velocity in the Russian population. This case highlights the importance of whole exome sequencing for a proper clinical diagnosis of CMT associated with a mutation in the MPZ gene.


Subject(s)
Charcot-Marie-Tooth Disease , Male , Humans , Child , Adult , Charcot-Marie-Tooth Disease/diagnosis , Charcot-Marie-Tooth Disease/genetics , Myelin P0 Protein/genetics , Mutation/genetics , Electromyography , Family
12.
Front Genet ; 13: 972196, 2022.
Article in English | MEDLINE | ID: mdl-36685848

ABSTRACT

We present the results of the depression Genome-wide association studies study performed on a cohort of Russian-descent individuals, which identified a novel association at chromosome 7q21 locus. Gene prioritization analysis based on already known depression risk genes indicated MAGI2 (S-SCAM) as the most probable gene from the locus and potential susceptibility gene for the disease. Brain and gut expression patterns were the main features highlighting functional relatedness of MAGI2 to the previously known depression risk genes. Local genetic covariance analysis, analysis of gene expression, provided initial suggestive evidence of hospital anxiety and depression scale and diagnostic and statistical manual of mental disorders scales having a different relationship with gut-brain axis disturbance. It should be noted, that while several independent methods successfully in silico validate the role of MAGI2, we were unable to replicate genetic association for the leading variant in the MAGI2 locus, therefore the role of rs521851 in depression should be interpreted with caution.

13.
J Virol ; 84(14): 6995-7004, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20463077

ABSTRACT

Human T-lymphotropic virus type 1 (HTLV-1) envelope (Env) glycoprotein mediates binding of the virus to its receptor on the surface of target cells and subsequent fusion of virus and cell membranes. To better understand the mechanisms that control HTLV-1 Env trafficking and activity, we have examined two protein-protein interaction motifs in the cytoplasmic domain of Env. One is the sequence YSLI, which matches the consensus YXXPhi motifs that are known to interact with various adaptor protein complexes; the other is the sequence ESSL at the C terminus of Env, which matches the consensus PDZ-binding motif. We show here that mutations that destroy the YXXPhi motif increased Env expression on the cell surface and increased cell-cell fusion activity. In contrast, mutation of the PDZ-binding motif greatly diminished Env expression in cells, which could be restored to wild-type levels either by mutating the YXXPhi motif or by silencing AP2 and AP3, suggesting that interactions with PDZ proteins oppose an Env degradation pathway mediated by AP2 and AP3. Silencing of the PDZ protein hDlg1 did not affect Env expression, suggesting that hDlg1 is not a binding partner for Env. Substitution of the YSLI sequence in HTLV-1 Env with YXXPhi elements from other cell or virus membrane-spanning proteins resulted in alterations in Env accumulation in cells, incorporation into virions, and virion infectivity. Env variants containing YXXPhi motifs that are predicted to have high-affinity interaction with AP2 accumulated to lower steady-state levels. Interestingly, mutations that destroy the YXXPhi motif resulted in viruses that were not infectious by cell-free or cell-associated routes of infection. Unlike YXXPhi, the function of the PDZ-binding motif manifests itself only in the producer cells; AP2 silencing restored the incorporation of PDZ-deficient Env into virus-like particles (VLPs) and the infectivity of these VLPs to wild-type levels.


Subject(s)
Amino Acid Motifs/genetics , Gene Products, env/metabolism , Human T-lymphotropic virus 1 , PDZ Domains , Tyrosine/genetics , Adaptor Protein Complex 2/genetics , Adaptor Protein Complex 2/metabolism , Adaptor Protein Complex 3/genetics , Adaptor Protein Complex 3/metabolism , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Cell Fusion , Cell Line , Discs Large Homolog 1 Protein , Gene Products, env/genetics , Human T-lymphotropic virus 1/genetics , Human T-lymphotropic virus 1/metabolism , Humans , Membrane Proteins/genetics , Membrane Proteins/metabolism , Molecular Sequence Data , PDZ Domains/genetics , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Tyrosine/metabolism
14.
Methods Mol Biol ; 1682: 91-102, 2018.
Article in English | MEDLINE | ID: mdl-29039096

ABSTRACT

Hemolysis is damage to red blood cells (RBCs), which results in the release of the iron-containing protein hemoglobin into plasma. An in vitro assay was developed and described earlier for the analysis of nanoparticle hemolytic properties. Herein, we present a revised version of the original protocol. In this protocol, analyte nanoparticles and controls are incubated in blood. Undamaged RBCs are removed by centrifugation and hemoglobin, released by the damaged erythrocytes, is converted to cyanmethemoglobin by incubation with Drabkin's reagent. The amount of cyanmethemoglobin in the supernatant is measured by spectrophotometry. This measured absorbance is compared to a standard curve to determine the concentration of hemoglobin in the supernatant. The measured hemoglobin concentration is then compared to the total hemoglobin concentration to obtain the percentage of nanoparticle-induced hemolysis. The revision includes updated details about nanoparticle sample preparation, selection of nanoparticle concentration for the in vitro study, updated details about assay controls and case studies about nanoparticle interference with the in vitro hemolysis assay.


Subject(s)
Erythrocytes/pathology , Hemolysis , Nanoparticles/adverse effects , Blood Specimen Collection/methods , Centrifugation/methods , Hemoglobins/analysis , Humans , Indicators and Reagents , Methemoglobin/analogs & derivatives , Methemoglobin/analysis , Spectrophotometry/methods
15.
Methods Mol Biol ; 1682: 149-160, 2018.
Article in English | MEDLINE | ID: mdl-29039100

ABSTRACT

The complement system is a group of proteins, which function in plasma to assist the innate immunity in rapid clearance of pathogens. The complement system also contributes to coordination of the adaptive immune response. Complement Activation Related Pseudo Allergy or CARPA is a life-threatening condition commonly reported with certain types of drugs and nanotechnology-based combination products. While CARPA symptoms are similar to that of anaphylaxis, the mechanism behind this pathology does not involve IgE and is mediated by the complement system. In vitro assays using serum or plasma derived from healthy donor volunteers correlate with the in vivo complement-mediated reactions, and therefore are helpful in understanding the propensity of a given drug formulation to cause CARPA in patients. In the first edition of this book, we have described an in vitro method for qualitative assessment of the complement activation by nanomaterials using western blotting. Herein, we present a similar method utilizing enzyme-linked immunoassay for quantitative analysis of the complement activation, and we compare the performance of this approach to that of the qualitative western blotting technique. The revised chapter also includes new details about nanoparticle sample preparation.


Subject(s)
Complement Activation , Immunoenzyme Techniques/methods , Nanoparticles/adverse effects , Blood Specimen Collection/methods , Blotting, Western/methods , Complement C3/analysis , Complement C3/immunology , Humans
16.
Methods Mol Biol ; 1682: 19-22, 2018.
Article in English | MEDLINE | ID: mdl-29039089

ABSTRACT

Bacterial contamination can confound the results of in vitro and in vivo preclinical tests. This protocol describes a procedure for detection of microbial contamination in nanotechnology-based formulations. Nanoparticle samples and controls are spread on the surface of agar and growth of bacterial colonies is monitored after 72 h of incubation. The intended purpose of this assay is to avoid introduction of microbial contamination into in vitro cell cultures and in vivo animal studies utilizing the test nanomaterial. This assay is not intended to certify the material as sterile.


Subject(s)
Bacteria/growth & development , Colony Count, Microbial/methods , Nanoparticles/microbiology , Agar/chemistry , Animals , Bacteria/isolation & purification , Equipment Contamination , Humans
17.
Methods Mol Biol ; 1682: 103-124, 2018.
Article in English | MEDLINE | ID: mdl-29039097

ABSTRACT

Blood clotting is a complex process which involves both cellular and biochemical components. The key cellular players in the blood clotting process are thrombocytes or platelets. Other cells, including leukocytes and endothelial cells, contribute to clotting by expressing the so-called pro-coagulant activity (PCA) complex on their surface. The biochemical component of blood clotting is represented by the plasma coagulation cascade, which includes plasma proteins also known as coagulation factors. The coordinated interaction between platelets, leukocytes, endothelial cells, and plasma coagulation factors is necessary for maintaining hemostasis and for preventing excessive bleeding. Undesirable activation of all or some of these components may lead to pathological blood coagulation and life-threatening conditions such as consumptive coagulopathy or disseminated intravascular coagulation (DIC). In contrast, unintended inhibition of the coagulation pathways may lead to hemorrhage. Thrombogenicity is the property of a test material to induce blood coagulation by affecting one or more elements of the clotting process. Anticoagulant activity refers to the property of a test material to inhibit coagulation. The tendency to cause platelet aggregation, perturb plasma coagulation, and induce leukocyte PCA can serve as an in vitro measure of a nanomaterial's likelihood to be pro- or anticoagulant in vivo. This chapter describes three procedures for in vitro analyses of platelet aggregation, plasma coagulation time, and activation of leukocyte PCA. Platelet aggregation and plasma coagulation procedures have been described earlier. The revision here includes updated details about nanoparticle sample preparation, selection of nanoparticle concentration for the in vitro study, and updated details about assay controls. The chapter is expanded to describe a method for the leukocyte PCA analysis and case studies demonstrating the performance of these in vitro assays.


Subject(s)
Blood Coagulation Tests/methods , Blood Coagulation , Materials Testing/methods , Nanoparticles/adverse effects , Platelet Function Tests/methods , Blood Specimen Collection/methods , Humans , Leukocytes/cytology , Leukocytes/metabolism , Nanoparticles/metabolism , Platelet Aggregation
18.
Methods Mol Biol ; 1682: 173-187, 2018.
Article in English | MEDLINE | ID: mdl-29039102

ABSTRACT

Cytokines, chemokines, and interferons are released by the immune cells in response to cellular stress, damage and/or pathogens, and are widely used as biomarkers of inflammation. Certain levels of cytokines are needed to stimulate an immune response in applications such as vaccines or immunotherapy where immune stimulation is desired. However, undesirable elevation of cytokine levels, as may occur in response to a drug or a device, may lead to severe side effects such as systemic inflammatory response syndrome or cytokine storm. Therefore, preclinical evaluation of a test material's propensity to cause cytokine secretion by healthy immune cells is an important parameter for establishing its safety profile. Herein, we describe in vitro methods for analysis of cytokines, chemokines, and type II interferon in whole blood cultures derived from healthy donor volunteers. First, whole blood is incubated with controls and tested nanomaterials for 24 h. Then, culture supernatants are analyzed by ELISA to detect IL-1ß, TNFα, IL-8, and IFNγ. The culture supernatants can also be analyzed for the presence of other biomarkers secreted by the immune cells. Such testing would require additional assays not covered in this chapter and/or optimization of the test procedure to include relevant positive controls and/or cell types.


Subject(s)
Cytokines/blood , Enzyme-Linked Immunosorbent Assay/methods , Inflammation/blood , Inflammation/etiology , Nanoparticles/adverse effects , Cytokines/immunology , Humans , Inflammation/immunology , Interferon-gamma/blood , Interferon-gamma/immunology , Interleukin-1beta/blood , Interleukin-1beta/immunology , Interleukin-8/blood , Interleukin-8/immunology , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/immunology
19.
Methods Mol Biol ; 1682: 125-133, 2018.
Article in English | MEDLINE | ID: mdl-29039098

ABSTRACT

This chapter provides a protocol for analysis of nanoparticle effects on the function of phagocytic cells. The protocol relies on luminol chemiluminescence to detect zymosan uptake. Zymosan is an yeast particle which is typically eliminated by phagocytic cells via the complement receptor pathway. The luminol, co-internalized with zymosan, is processed inside the phagosome to generate a chemiluminescent signal. If a test nanoparticle affects the phagocytic function of the cell, the amount of phagocytosed zymosan and, proportionally, the level of generated chemiluminescent signal change. Comparing the zymosan uptake of untreated cells with that of cells exposed to a nanoparticle provides information about the nanoparticle's effects on the normal phagocytic function. This method has been described previously and is presented herein with several changes. The revised method includes details about nanoparticle concentration selection, updated experimental procedure, and examples of the method performance.


Subject(s)
Luminescent Measurements/methods , Phagocytes/cytology , Phagocytosis , Zymosan/analysis , HL-60 Cells , Humans , Luminol/analysis , Phagocytes/immunology , Zymosan/immunology
20.
Adv Exp Med Biol ; 601: 205-10, 2007.
Article in English | MEDLINE | ID: mdl-17713007

ABSTRACT

Under the influence of dimeric glucosaminylmuramyl pentapeptide (diGMPP), a component of bacterial cell wall, macrophages undergo certain changes similar to those associated with dendritic cell (DC) maturation. The effect of diGMPP on DCs resulted in maturation and expression of CD83. Macrophages treated with diGMPP displayed reduced phagocytic activity and elevated ability to kill ingested bacteria. Reduced phagocytosis may be due to phenotypic changes that occur in macrophages during the maturation process, such as reduced expression of receptors that mediate ingesting of microorganisms (CD16, CD64, and CD11b). Down-regulated expression of pattern-recognizing receptors (TLR2, TLR4, and CD206) was accompanied by elevated expression of antigen-presenting (HLA-DR) and costimulating molecules (CD86 and CD40), similar to alterations observed in maturating DCs. In addition, diGMPP treatment of macrophages resulted in enhanced synthesis of IL-12, TNF-alpha, and IL-1beta.


Subject(s)
Cytokines/metabolism , Gene Expression Regulation , Macrophages/physiology , Oligopeptides/pharmacology , Peptides/pharmacology , Antigens, CD/biosynthesis , Dimerization , Down-Regulation , Immunoglobulins/biosynthesis , Inflammation , Interleukin-12/metabolism , Interleukin-1beta/metabolism , Macrophages/metabolism , Membrane Glycoproteins/biosynthesis , Models, Biological , Oligopeptides/chemistry , Phagocytosis , Salmonella typhi/metabolism , Tumor Necrosis Factor-alpha/metabolism , CD83 Antigen
SELECTION OF CITATIONS
SEARCH DETAIL